TS-1 combination OD tablet specific use-results survey To evaluate safety of tegafur, gimeracil, oteracil potassium combination OD tablet
Not Applicable
Completed
- Conditions
- Gastric cancer
- Registration Number
- JPRN-jRCT1080222542
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
1. Histologically proven gastric cancer
2. Residual tumor R0 or R1 after surgery
3. Started chemotherapy within 6 weeks after surgery
4. No previous treatment for cancer except for the initial gastric resection for the primary lesion
5. No multiple primary cancer or multicentric cancer
6. No serious postoperative complication
7. Informed consent for treatment
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of adverse drug reactions (until 1 year after surgery)<br>The frequency of adverse events will be tabulated by type, seriousness, causal relationship, time of onset, etc.
- Secondary Outcome Measures
Name Time Method